中国现代医药杂志
中國現代醫藥雜誌
중국현대의약잡지
MODERN MEDICINE JOURNAL OF CHINA
2014年
9期
54-56
,共3页
化疗%大肠癌%免疫功能%淋巴细胞
化療%大腸癌%免疫功能%淋巴細胞
화료%대장암%면역공능%림파세포
Chemotherapy%Colorectal cancer%Immune function%Lymphocyte
目的：探讨 FOLFIRI（伊立替康+5-氟尿嘧啶+亚叶酸钙）及 FOLFOX4（奥沙利铂+5-氟尿嘧啶+亚叶酸钙）对大肠癌患者淋巴细胞亚群的影响。方法74例大肠癌患者中接受 FOLFIRI 及 FOLFOX4治疗各37例，比较治疗前后患者体内淋巴细胞亚群的变化。结果化疗后两组患者外周血中 CD3+、CD3+CD8+、CD4+CD25+、CD29+细胞比例分别较化疗前升高（t=7.11～12.32，P<0.05）。 FOLFOX4组化疗后 CD19+细胞比例低于化疗前（t=5.47，P=0.039），FOLFIRI 组 CD19+细胞比例与化疗前差异无统计学意义（t=1.28，P=0.915）。化疗后，FOLFIRI 组 CD19+细胞比例高于 FOLFOX4组（t=5.88，P=0.031），其余各项检测指标两组比较差异无统计学意义（t=1.04～2.23，P>0.05）。结论化疗一定程度地影响了大肠癌患者淋巴细胞亚群的比例，使机体免疫细胞比例一定程度上升，但 FOLFOX4降低了 CD19+的比例。
目的：探討 FOLFIRI（伊立替康+5-氟尿嘧啶+亞葉痠鈣）及 FOLFOX4（奧沙利鉑+5-氟尿嘧啶+亞葉痠鈣）對大腸癌患者淋巴細胞亞群的影響。方法74例大腸癌患者中接受 FOLFIRI 及 FOLFOX4治療各37例，比較治療前後患者體內淋巴細胞亞群的變化。結果化療後兩組患者外週血中 CD3+、CD3+CD8+、CD4+CD25+、CD29+細胞比例分彆較化療前升高（t=7.11～12.32，P<0.05）。 FOLFOX4組化療後 CD19+細胞比例低于化療前（t=5.47，P=0.039），FOLFIRI 組 CD19+細胞比例與化療前差異無統計學意義（t=1.28，P=0.915）。化療後，FOLFIRI 組 CD19+細胞比例高于 FOLFOX4組（t=5.88，P=0.031），其餘各項檢測指標兩組比較差異無統計學意義（t=1.04～2.23，P>0.05）。結論化療一定程度地影響瞭大腸癌患者淋巴細胞亞群的比例，使機體免疫細胞比例一定程度上升，但 FOLFOX4降低瞭 CD19+的比例。
목적：탐토 FOLFIRI（이립체강+5-불뇨밀정+아협산개）급 FOLFOX4（오사리박+5-불뇨밀정+아협산개）대대장암환자림파세포아군적영향。방법74례대장암환자중접수 FOLFIRI 급 FOLFOX4치료각37례，비교치료전후환자체내림파세포아군적변화。결과화료후량조환자외주혈중 CD3+、CD3+CD8+、CD4+CD25+、CD29+세포비례분별교화료전승고（t=7.11～12.32，P<0.05）。 FOLFOX4조화료후 CD19+세포비례저우화료전（t=5.47，P=0.039），FOLFIRI 조 CD19+세포비례여화료전차이무통계학의의（t=1.28，P=0.915）。화료후，FOLFIRI 조 CD19+세포비례고우 FOLFOX4조（t=5.88，P=0.031），기여각항검측지표량조비교차이무통계학의의（t=1.04～2.23，P>0.05）。결론화료일정정도지영향료대장암환자림파세포아군적비례，사궤체면역세포비례일정정도상승，단 FOLFOX4강저료 CD19+적비례。
Objective To investigate the effect of FOLFIRI (irinotecan +5-fluorouracil plus leucovorin) and FOLFOX4 (oxaliplatin and +5-fluorouracil plus leucovorin) on lymphocyte subgroups in patients with colorectal cancer. Methods 74 colorectal cancer patients were selected. 37 cases of them received FOLFIRI and the rest received FOLFOX4. Compared the changes of lymphocyte subgroups before and after treatment. Results After chemotherapy, the CD3+,CD3+CD8+,CD4+CD25+, CD29+ cell proportion in peripheral blood of the two groups respectively increased (t=7.11~12.32, P<0.05). The CD19 + cell proportion in FOLFOX4 group after chemotherapy was less than pre-chemotherapy (t=5.47, P=0.039),while the FOLFIRI group had no statistically significant difference compared with pre-chemotherapy (t=1.28, P=0.915). After chemotherapy, the percentage of CD19+ cells in FOLFIRI group was higher than that of FOLFOX4 group (t=5.88, P=0.031), the rest of the indexes between the two groups had no statistical significance (t=1.04~2.23, P>0.05). Conclusion Chemotherapy could make a cer-tain effect on the proportion of lymphocyte subgroups and give rise to immune cells, but FOLFOX4 could decrease the CD19 +cells ratio.
